National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 66317 [2022-23897]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 212 / Thursday, November 3, 2022 / Notices
Dated: October 28, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23878 Filed 11–2–22; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Centers for AIDS Research
(P30 Clinical Trial Not Allowed);
Developmental Centers for AIDS Research
(P30 Clinical Trial Not Allowed).
Date: December 5–6, 2022.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Cynthia L. De La Fuente,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20852, 240–669–2740,
delafuentecl@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 28, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
VerDate Sep<11>2014
16:41 Nov 02, 2022
Jkt 259001
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2022–23897 Filed 11–2–22; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Project: Notification of Intent To Use
Schedule III, IV, or V Controlled
Medications for the Treatment of
Opioid Use Disorder Under 21 U.S.C.
823(g)(2) (OMB No. 0930–0234 and
OMB No. 0930–0369)—Revision
The Drug Addiction Treatment Act of
2000 (‘‘DATA,’’ Pub. L. 106–310)
amended the Controlled Substances Act
(21 U.S.C. 823(g)(2)) to permit
qualifying practitioners to seek and
obtain waivers to prescribe certain
approved controlled medications for the
treatment of opioid use disorder. The
legislation set eligibility and
certification requirements as well as an
interagency notification review process
for practitioners who seek waivers. To
implement these provisions, SAMHSA
developed Notification of Intent Forms
that facilitate the submission and review
of notifications. The forms provide the
information necessary to determine
whether practitioners meet the
qualifications for waivers set forth
under the law at the 30-, 100-, and 275patient limits. This includes the annual
reporting requirements for practitioners
with waivers for a 275-patient limit. On
October 24, 2018, the Substance Use
Disorder Prevention that Promotes
Opioid Recovery and Treatment for
Patients and Communities (SUPPORT)
Act (Pub. L. 115–71) was signed into
law. Sections 3201–3202 of the
SUPPORT Act made several
amendments to the Controlled
Substances Act regarding office-based
opioid use disorder treatment that
affords practitioners greater flexibility in
the provision of Medications for Opioid
Use Disorder (MOUD).
The SUPPORT Act expands the
definition of ‘‘qualifying other
practitioner’’ enabling Clinical Nurse
Specialists, Certified Registered Nurse
Anesthetists, and Certified Nurse
Midwives (CNSs, CRNAs, and CNMs) to
apply for a Drug Addiction Treatment
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
66317
Act of 2000 (DATA) waiver until
October 1, 2023. It also allows qualified
practitioners (i.e., MDs, DOs, NPs, PAs,
CNSs, CRNAs, and CNMs) who are
board certified in addiction medicine or
addiction psychiatry, -or- practitioners
who provide MOUD in a qualified
practice setting, to start treating up to
100 patients in the first year of practice
(as defined in 42 CFR 8.2) with a
waiver. Further, the SUPPORT Act
extends the ability to treat up to 275
patients to ‘‘qualifying other
practitioners’’ (i.e., NPs, PAs, CNSs,
CRNAs, and CNMs) if they have a
waiver to treat up 100 patients for at
least one year and provide treatment of
Opioid Use Disorder with covered
medications (as such terms are defined
under 42 CFR 8.2) in a qualified practice
setting as described under 42 CFR 8.615.
Finally, the SUPPORT Act also expands
how physicians could qualify for a
waiver. Under the statute now,
physicians can qualify for a waiver if
they have received at least 8 hours of
training on treating and managing
patients with opioid use disorder, as
listed in the statute if the physician
graduated in good standing from an
accredited school of allopathic medicine
or osteopathic medicine in the United
States during the 5-year period
immediately preceding the date on
which the physician submits a Notice of
Intent to SAMHSA. In order to expedite
the new provisions of the SUPPORT
Act, SAMHSA sought and received a
Public Health Emergency Paperwork
Reduction Act Waiver.
On April 28, 2021 the Department of
Health and Human Services (HHS)
issued the new Practice Guidelines for
the Administration of Buprenorphine
for Treating Opioid Use Disorder (86 FR
22439) in an expedited manner. The
Practice Guidelines allow practitioners
who wish to obtain a 30-patient waiver
to forego the 8-hour training
requirement for physicians and 24-hour
training for other qualifying
practitioners. Practitioners utilizing this
training exemption are limited to
treating no more than 30-patients at a
time and time spent practicing under
this exemption will not qualify the
practitioner to qualify for a higher
patient level. In addition, the new
Practice Guidelines removed the
requirement to provide counseling and
other ancillary services (i.e.,
psychosocial services).
The collection of information within
the application is essential to the
implementation of SAMHSA’s mission
to reduce the impact of substance use
disorders on America’s communities.
Practitioners may use these forms for
various types of notifications: (a) New
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 87, Number 212 (Thursday, November 3, 2022)]
[Notices]
[Page 66317]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23897]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Centers for AIDS Research (P30
Clinical Trial Not Allowed); Developmental Centers for AIDS Research
(P30 Clinical Trial Not Allowed).
Date: December 5-6, 2022.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Cynthia L. De La Fuente, Ph.D., Scientific
Review Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G31,
Rockville, MD 20852, 240-669-2740, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 28, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-23897 Filed 11-2-22; 8:45 am]
BILLING CODE 4140-01-P
